CVS admitted over-dispensing insulin for a decade. The price was $37.76 million.

By ··1 min read·2 sources

The admission is rare. The penalty, spread over ten years of conduct across the country's largest pharmacy chain, is small.

CVS Pharmacy agreed on December 2, 2025, to pay $37.76 million over insulin-pen refills from 2010 to 2020. About $24.4 million goes to the federal government and the rest to states.

The government said CVS refilled prescriptions early, dispensed more pens than prescribed, and under-reported days-of-supply so claims would be paid. CVS admitted that government programs paid for ineligible refills and that patients received more insulin than they needed.

The detail that should worry regulators is who noticed. PBM audits repeatedly found the violations, and the practice continued for a decade. The government's complaint said CVS management knew. CVS's response was that insulin-pen billing is "incredibly complex".

An admission closes the case. At under $4 million a year of conduct, it does not make the practice expensive.

Sources

  1. justice.gov · justice.gov/usao-sdny/pr/us-attorney-announces-3776-million-settlement-cvs-over-dispensing…
  2. supermarketnews.com · supermarketnews.com/nonfood-pharmacy/cvs-will-pay-almost-38m-to-settle-charges-of-over-dis…

Cite this report

The Precedent. "CVS admitted over-dispensing insulin for a decade. The price was $37.76 million.." September 14, 2026. https://theprecedent.org/article/cvs-admitted-over-dispensing-insulin-for-a-decade-the-price-was-3776-million

Companies in this report